Rapport Therapeutics Shares Surge After Phase 2 Trial Success
Rapport Therapeutics reported a successful Phase 2 trial, prompting a surge in its shares. The source frames the opportunity as potentially worth $1 billion.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.